Shorted
Cynata Therapeutics logo
CYP
Pharmaceuticals, Biotechnology & Life Sciences

Cynata Therapeutics

Short interest
0.00%
−0.62 pp 30d
as of 13 May 2026
Reported shorts
3.1K
Shares on issue
243.454M

Cynata Therapeutics (CYP) company profile

Profile, insiders and operations

Company

AI-generated research profile of Cynata Therapeutics

Biotechnology
Cell Therapy
Regenerative Medicine
Clinical Stage
ASX:CYP

Cynata Therapeutics is a clinical-stage biotechnology company focused on developing and commercialising its proprietary Cymerus™ platform technology, which generates induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs). This innovative platform provides a scalable and consistent source of MSCs, positioning Cynata as a potential leader in 'off-the-shelf' regenerative medicine with applications across various inflammatory, autoimmune, and degenerative diseases.

Director trades

16 trades recorded

DateDirectorTypeSharesPriceValue
2025-12-01Dr Paul Wotton
buy
---
2025-12-01Dr Darryl Maher
buy
---
2025-12-01Dr Geoff Brooke
buy
---
2025-11-29Darryl Maher
other
300,000--
2025-11-29Paul K Wotton
other
300,000--
2025-11-29Geoffrey Brooke
other
2,000,000--
2025-04-01Geoffrey Brooke
sell
85,515--
2025-04-01Unknown Director
buy
---
2025-02-20Paul K Wotton
exercise options
69,767$0.300$20,930.1
2025-02-20Paul Wotton
buy
---
2025-01-23Geoffrey Brooke
buy
233,332$0.180$41,999.76
2025-01-23Unknown Director
buy
---
2024-08-19Dr Kilian Kelly
buy
---
2024-08-18Kilian Kelly
other
1,000,000--
2024-05-17Dr Geoffrey Brooke
buy
---
2024-05-16Geoffrey Brooke
other
300,000--

CYP intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required